Clinical Trial Update: Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating paclitaxel, carboplatin, and bevacizumab with or without Cixutumumab in stage IV or recurrent non-small cell lung cancer; the study was…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchioloalveolar Carcinoma
• Large Cell Lung Carcinoma
• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Cixutumumab (Cixutumumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Large Cell Lung Carcinoma, Lung Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2016-09-08